Login
CORCEPT THERAPEUTICS INC logo

CORCEPT THERAPEUTICS INC

corcept.com

What Do They Do?

Sells medicines for people with hypercortisolism and develops cortisol-modulating treatments for patients with cancer and other serious disorders.

How Do They Make Money?

Corcept sells its medicines to patients through specialty pharmacy vendors and to a specialty distributor. It gets paid when products are delivered; patients need insurance or third-party charity coverage before a sale.

FY2025 revenue

Who Are Their Customers?

Patients receive Corcept’s medicines through specialty pharmacy vendors, while a specialty distributor also buys the products. Sales representatives call on physicians who treat hypercortisolism.

Do Revenues Turn Into Profits?

Yes. It kept 13 cents of every revenue dollar as net income in FY2025 and turned 19 cents into free cash flow.

Operating income, FY2025
6% of revenue
▼ −67% vs FY2024 ($137M, 20%)
Net income, FY2025
13% of revenue
▼ −29% vs FY2024 ($141.2M, 21%)
Free cash flow, FY2025
19% of revenue
▼ −28% vs FY2024 ($196.1M, 29%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +64%
vs $207.6M in Q3 FY2025
Net income
▲ +545%
vs $19.7M in Q3 FY2025
  • Jul 29, 2026 Raised 2026 revenue guidance Corcept raised its 2026 revenue guidance to $1.1 – $1.2 billion.
  • Mar 25, 2026 FDA approved Lifyorli for platinum-resistant ovarian cancer The approval is for Lifyorli in combination with nab-paclitaxel.

Growing. Revenue grew 2.1x in 4 years, from $366M in FY2021 to $761.4M in FY2025, about 20% a year.

Added an authorized generic The older report described Korlym as the marketed medicine; the latest report also says an authorized generic version is available and sold.

Broadened cancer research The older report described work in ovarian, adrenal and prostate cancers; the latest report also lists endometrial, cervical and pancreatic cancers among the targets.

Who Do They Compete With?

Competes with Recordati, Xeris Biopharma Holdings, and Teva Pharmaceuticals USA

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support